<code id='098446C379'></code><style id='098446C379'></style>
    • <acronym id='098446C379'></acronym>
      <center id='098446C379'><center id='098446C379'><tfoot id='098446C379'></tfoot></center><abbr id='098446C379'><dir id='098446C379'><tfoot id='098446C379'></tfoot><noframes id='098446C379'>

    • <optgroup id='098446C379'><strike id='098446C379'><sup id='098446C379'></sup></strike><code id='098446C379'></code></optgroup>
        1. <b id='098446C379'><label id='098446C379'><select id='098446C379'><dt id='098446C379'><span id='098446C379'></span></dt></select></label></b><u id='098446C379'></u>
          <i id='098446C379'><strike id='098446C379'><tt id='098446C379'><pre id='098446C379'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:35
          Two boxes of fluticadone propionate. It's used to treat asthma in children and adults. It’s the generic version of the brand name drug Flovent. -- health coverage from STAT
          Boston Globe

          A commonly prescribed medication for children’s asthma is disappearing from pharmacists’ shelves, forcing parents and pediatricians to scramble for alternatives just as allergy season is about to start.

          In a move unusual for such a widely used drug, GlaxoSmithKline discontinued Flovent HFA, the brand name of its corticosteroid treatment fluticasone propionate, at the end of December. Critics, including Massachusetts Senator Elizabeth Warren, say the decision helps the company avoid new Medicaid penalties going into effect this year for medications with price increases that outpace inflation.

          advertisement

          “It was all very confusing, and we were left scrambling, trying to find out what we could do,” said Simone Fung, whose 5-year-old son, David, endured worse asthma symptoms over the past two months as the Cambridge family navigated confusing insurance policies and shortages of alternative medications to find a replacement for Flovent.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Medicare Advantage enrollment grows 7.1% to 33.4 million people
          Medicare Advantage enrollment grows 7.1% to 33.4 million people

          PabloMartinezMonsivais/APRoughly33.4millionadultsolderthan65andpeoplewithdisabilitieswereenrolledina

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Medicare Advantage enrollment grows 7.1% to 33.4 million people

          PabloMartinezMonsivais/APRoughly33.4millionadultsolderthan65andpeoplewithdisabilitieswereenrolledina